HC Wainwright reaffirmed their buy rating on shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) in a research report sent to investors on Thursday. They currently have a $3.50 price target on the biotechnology company’s stock.
A number of other equities research analysts have also issued reports on PSTI. Maxim Group reaffirmed a buy rating and set a $2.00 target price on shares of Pluristem Therapeutics in a research report on Tuesday, September 5th. ValuEngine raised Pluristem Therapeutics from a strong sell rating to a sell rating in a research report on Monday, October 2nd. Zacks Investment Research lowered Pluristem Therapeutics from a hold rating to a sell rating in a research report on Friday, September 22nd. Finally, Seaport Global Securities reaffirmed a buy rating and set a $5.00 target price on shares of Pluristem Therapeutics in a research report on Friday, October 6th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $4.38.
Shares of Pluristem Therapeutics (NASDAQ PSTI) opened at $1.43 on Thursday. Pluristem Therapeutics has a 52-week low of $1.04 and a 52-week high of $2.12.
Large investors have recently bought and sold shares of the stock. Heritage Investors Management Corp acquired a new position in Pluristem Therapeutics during the third quarter valued at $113,000. Jane Street Group LLC raised its position in Pluristem Therapeutics by 62.4% during the first quarter. Jane Street Group LLC now owns 108,830 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 41,796 shares during the period. Finally, Renaissance Technologies LLC raised its position in Pluristem Therapeutics by 9.1% during the first quarter. Renaissance Technologies LLC now owns 1,553,800 shares of the biotechnology company’s stock valued at $1,911,000 after buying an additional 129,000 shares during the period. 4.09% of the stock is currently owned by hedge funds and other institutional investors.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.